Skip to main content

Delphi advises on significant pharma deal

Pressmeddelande   •   Nov 03, 2011 10:17 CET

Delphi has been legal advisor to DuoCort AB in connection with the sale of its subsidiary DuoCort Pharma AB to the NASDAQ listed biopharmaceutical company Viropharma Inc. Delphi’s team consisted of Anders Jemail (partner), Per Lagerkvist (partner) and Micael Karlsson (associate).

Just recently it was announced that Viropharma Inc. and DuoCort AB signed an agreement on the acquisition of DuoCort Pharma AB. DuoCort Pharma has developed the orphan drug Plenadren, a new treatment for adrenal insufficiency also called Addison´s disease. The deal is conditioned upon receipt of market authorization for Plenadren within EU. At closing an upfront purchase price of SEK 220 million will be paid with the possibility of additional SEK 860 million in various milestone payments.

 

Contact:
Anders Jemail
Partner
Delphi
Mobile; +46 709 252607

 

www.delphi.se


-------

Delphi has specialist knowledge in all core areas of business law. An important part is Corporate Finance with many mergers and acquisitions, and extensive activities within banking, finance and capital markets. The firm also has a high profile in  high tech areas such as IT, telecommunications, IP and life sciences and has a well-reputed practice group for  public procurements, EU and competition law. Our clients come primarily from Scandinavia, Europe and North America. Delphi cooperates with law firms all over the world and has a practice in China and Eastern Europe. Delphi has more than 190 employees, of which 140 are lawyers. The firm has offices in Stockholm, Göteborg, Malmö, Linköping and Norrköping.

Bifogade filer

PDF-dokument

Kommentarer (0)

Lägg till kommentar

Kommentera